跳至主要内容
临床试验/CTRI/2018/02/011933
CTRI/2018/02/011933尚未招募未知

Assessment of Clinical Profile of Patients of Chronic Heart Failure with Iron Deficiency Treated with Intravenous Ferric Carboxymaltose 1000 mg:- PRIDE-HF India Study - PRIDE-HF India

Emcure Pharmaceuticals Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. Indian adult ( >18 years of age) patients of either gender who are capable of complying with study protocol
  • requirements
  • 2. Stable ambulatory patients with chronic heart failure of New York Heart Association (NYHA) class I â?? IV and iron
  • deficiency. Iron deficiency is diagnosed when the serum ferritin level is less than 100 μg/L or is between 100 and 299
  • μg/L when the transferrin saturation (TSAT) is less than 20%
  • 3. Patients treated with injection ferric carboxymaltose 1000 mg as per approved prescribing information.
  • 4. Patients whose ejection fraction, serum ferritin and Hb levels are available at the start of FCM therapy.

排除标准

  • 1. Patients with incomplete health record as per the requirement of protocol
  • 2. Patients not willing to sign Informed Consent Form and provide medical data
  • 3. Pregnant and lactating women

研究者

相似试验